CA2269646A1 - Proteines mediatrices du diabete et leurs utilisations therapeutiques - Google Patents

Proteines mediatrices du diabete et leurs utilisations therapeutiques Download PDF

Info

Publication number
CA2269646A1
CA2269646A1 CA002269646A CA2269646A CA2269646A1 CA 2269646 A1 CA2269646 A1 CA 2269646A1 CA 002269646 A CA002269646 A CA 002269646A CA 2269646 A CA2269646 A CA 2269646A CA 2269646 A1 CA2269646 A1 CA 2269646A1
Authority
CA
Canada
Prior art keywords
diabetes
protein
expression
mediating
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002269646A
Other languages
English (en)
Inventor
Peter Mose Larsen
Stephen J. Fey
Jorn Nerup
Allan E. Karlsen
Ulla Bjerre Christensen
Flemming Pociot
Henrik U. Andersen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2269646A1 publication Critical patent/CA2269646A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T7/00—Image analysis
    • G06T7/0002—Inspection of images, e.g. flaw detection
    • G06T7/0012—Biomedical image inspection
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0325—Animal model for autoimmune diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2550/00—Electrophoretic profiling, e.g. for proteome analysis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Environmental Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Public Health (AREA)
  • Emergency Medicine (AREA)
  • Plant Pathology (AREA)
  • Obesity (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)

Abstract

L'invention concerne des protéines médiatrices du diabète, protectrices et néfastes, les polynucléotides codant pour lesdites protéines, des animaux transgéniques exprimant une protéine médiatrice du diabète, des méthodes de criblage de médicaments qui permettent d'identifier un composé test capable de modifier l'expression desdites protéines, ainsi que des méthodes qui permettent de prévenir ou d'améliorer le diabète en administrant un composé capable de modifier l'expression d'une protéine médiatrice du diabète.
CA002269646A 1996-10-25 1997-10-24 Proteines mediatrices du diabete et leurs utilisations therapeutiques Abandoned CA2269646A1 (fr)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US2932496P 1996-10-25 1996-10-25
US60/029,324 1996-10-25
US3018696P 1996-11-05 1996-11-05
US3008896P 1996-11-05 1996-11-05
US60/030,088 1996-11-05
US60/030,186 1996-11-05
US89709897A 1997-07-18 1997-07-18
US08/897,098 1997-07-18
PCT/IB1997/001627 WO1998020124A2 (fr) 1996-10-25 1997-10-24 Proteines mediatrices du diabete et leurs utilisations therapeutiques

Publications (1)

Publication Number Publication Date
CA2269646A1 true CA2269646A1 (fr) 1998-05-14

Family

ID=27487746

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002269646A Abandoned CA2269646A1 (fr) 1996-10-25 1997-10-24 Proteines mediatrices du diabete et leurs utilisations therapeutiques

Country Status (5)

Country Link
EP (1) EP0934409A2 (fr)
JP (2) JP2002504806A (fr)
AU (1) AU5407098A (fr)
CA (1) CA2269646A1 (fr)
WO (1) WO1998020124A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2286899T3 (es) 1998-10-27 2007-12-01 Suntory Limited Metodo para preparar un regulador metabolico de la glucolitica.
AU2376200A (en) * 1999-01-07 2000-07-24 Incyte Pharmaceuticals, Inc. Insulin-synthesis genes
AU773329B2 (en) * 1999-05-14 2004-05-20 Proteomedica Ab Materials and methods relating to disease diagnosis
WO2002097434A1 (fr) * 2001-05-29 2002-12-05 Syddansk Universitet Proteines utiles dans l'analyse proteomique du diabete
US7470542B2 (en) 2001-09-05 2008-12-30 Pride Proteomics A/S Proteins in type 2 diabetes
EP2071338A3 (fr) * 2002-03-20 2009-07-22 Pride Proteomics A/S Protéines liées au diabète humain

Also Published As

Publication number Publication date
JP2002504806A (ja) 2002-02-12
JP2008195721A (ja) 2008-08-28
WO1998020124A3 (fr) 1998-10-08
EP0934409A2 (fr) 1999-08-11
AU5407098A (en) 1998-05-29
WO1998020124A2 (fr) 1998-05-14

Similar Documents

Publication Publication Date Title
US7531323B2 (en) Diabetes-mediating proteins and therapeutic uses thereof
Rich et al. Effect of deleting the R domain on CFTR-generated chloride channels
US7186694B2 (en) Leptin-related peptides
Schinkel The physiological function of drug-transporting P-glycoproteins
Berger et al. Parkin selectively alters the intrinsic threshold for mitochondrial cytochrome c release
CZ20032706A3 (cs) Izolovaný polypeptid a nukleová kyselina a farmaceutický přípravek, který je obsahuje, pro diagnostiku, prevenci a léčení degenerativních onemocnění sitníce
JP2008195721A (ja) 糖尿病媒介タンパク質およびその治療的使用
Fleming et al. Characterization of a murine high-affinity thiamine transporter, Slc19a2
WO1997045128A1 (fr) Proteine bbk associee a l'apoptose
US20050031605A1 (en) Compositions and methods of treating diabetes
CN100549165C (zh) 华支睾吸虫钙调磷酸酶，其编码核酸及其应用
EP1609862A1 (fr) Protéines médiatrices de diabetes et leurs utilisations thérapeutiques
AU1557702A (en) Diabetes-mediating proteins and therapeutic uses thereof
CN100360665C (zh) 华支睾吸虫i类醛脱氢酶，其编码核酸及其应用
WO2002059369A2 (fr) Compositions et procedes de traitement des maladies liees a une mauvaise regulation du cholesterol
US20040235769A1 (en) Anti-tumor effects of prostage Carcinoma Tumor Antigen-1
JPH11103867A (ja) Ｅｐｏ一次応答遺伝子１、ｅｐｒｇ１
CN100374559C (zh) 华支睾吸虫蛋白酶体亚单位c3，其编码核酸及其应用
ES2222959T3 (es) Polipeptidos pro241 y acido nucleico codificante de los mismos.
Waterman An investigation into the role of autoimmunity in vitiligo
Xiong Pancreatic Islet-specific Overexpression of Reg3β protein
Preston Ferrer Functional analysis of the potassium channel beta subunit KCNE3
MXPA00005354A (en) Polypeptides and nucleic acids encoding the same
KR20040030145A (ko) 신규 폴리펩티드 및 이를 코딩하는 핵산
JPH11113583A (ja) 新規化合物

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead